Drugs / OTOV101N
OTOV101N
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05901480 | Jun 2023 → Dec 2024 | autosomal recessive nonsyndromic hearing loss 9 | Otovia Therapeutics | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OTOV101N | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05901480 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “adeno-associated virus (AAV)-OTOF gene therapy” PMID 40603731 ↗ Jul 2025 |
| Route | Other | “via intracochlear injection” NCT05901480 ↗ |
| Target | OTOF | “AAV-OTOF gene therapy” PMID 40603731 ↗ Jul 2025 |